GENEVA, July 31 -- DANA-FARBER CANCER INSTITUTE, INC. filed a patent application (US2026/012447) for “RECEPTOR-MEDIATED ENDOCYTOSIS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS WITH LOW OFF-TARGET EFFECTS”. With publication no. WO/2026/161762, here are the other details related to the patent application:
Kind: Initial Publication with ISR [A1]
IPC: A61K 39/395
Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).
Disclaimer: Curated by HT Syndication....